Copenhagen, Oct. 2020
SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, today announced the appointment of Dr. Milan Zdravkovic, MD, PhD as Chief Medical Officer from 01 November 2020. Dr. Zdravkovic will lead SNIPR Biome’s development activities.
Before joining SNIPR Biome, Dr. Zdravkovic was most recently Chief Medical Officer and Head of R&D at Swedish Orphan Biovitrum AB. Prior to that Dr. Zdravkovic had an 18-year tenure at Novo Nordisk including numerous Corporate Vice President roles heading up several therapeutic areas.
Dr. Christian Grøndahl, Co-founder & CEO commented: “We warmly welcome Milan to the SNIPR BIOME executive management team. Milan’s 20+ year trajectory in senior roles successfully leading drug development teams is a significant strengthening of our company. Milan has been engaged in numerous translational successes and development programs leading to drug approvals. His unique experience and track record bring valuable insights in a variety of disease areas and supports our commitment to pursuing CRISPR-based medicines to treat life threatening infections, as well as improve the treatment of inflammatory and malignant disorders.”
Dr. Milan Zdravkovic commented: “I am delighted to join SNIPR BIOME at this important point in the company’s growth and help drive the company forward. I am impressed with the team that Christian has assembled and the ground-breaking technological platform. I intend to build on the progress achieved so far and realise the enormous potential to deliver novel therapeutics for diseases with high unmet needs”
Dr. Zdravkovic holds an MD and PhD from University of Aarhus, Denmark and an MSc in Pharmaceutical Medicine from University of Surrey, UK. In addition, he has received training in management and strategy from Harvard and INSEAD.
For more information, please contact:
Co-founder & CEO, Christian Grøndahl / E-mail: email@example.com / Mobile: +45 20202747
About SNIPR BIOME
SNIPR BIOME is a leading CRISPR and microbiome biotech company incorporated in Copenhagen, Denmark. SNIPR BIOME is engaged in the discovery and development of CRISPR/Cas-based drugs deploying its proprietary and patent-protected CRISPR/Cas platform. The company applies its CRISPR technologies to address medical needs, such as infectious diseases, inflammatory conditions and immuno-oncology. SNIPR BIOME is pioneering a novel use of CRISPR/Cas technology to selectively and precisely eradicate target bacteria, while leaving the rest of the patient’s microbial community intact. In March 2019, SNIPR BIOME closed a $50 million Series A financing by Lundbeckfonden Emerge (Copenhagen), Life Sciences Partners (Amsterdam), North-East Family Office (Copenhagen) and Wellington Partners (Munich).
For more details, please visit: www.sniprbiome.com